Semaglutide: Beyond Weight Loss — A Physician's Assessment

Let me be direct about semaglutide: it is among the most important pharmacological developments of the past decade. The clinical data is robust, the effect sizes are large, and the implications extend well beyond weight loss. It is also wildly overhyped in some circles and reflexively dismissed in others. Neither response serves patients.

What I tell the patients I coach through this decision is this: semaglutide is a powerful tool with real benefits and real trade-offs. Whether it belongs in your treatment plan depends on your specific clinical situation, your goals, and your willingness to pair it with the lifestyle measures that make it sustainable. Here is what the evidence shows.

At a Glance

The GLP-1 Mechanism

Glucagon-like peptide-1 (GLP-1) is an incretin hormone produced by L-cells in the small intestine in response to food intake. Its physiological roles include:

• Stimulating glucose-dependent insulin secretion: it enhances insulin release only when blood glucose is elevated, which is why GLP-1 agonists carry low hypoglycemia risk
• Suppressing glucagon secretion: reducing hepatic glucose output
• Slowing gastric emptying: extending satiety after meals
• Central appetite regulation: GLP-1 receptors in the hypothalamus and brainstem reduce hunger and increase satiation

Native GLP-1 has a half-life of approximately two minutes — it is rapidly degraded by dipeptidyl peptidase-4 (DPP-4). Semaglutide is an engineered GLP-1 analog with 94% homology to native GLP-1, modified with a fatty acid side chain that enables albumin binding. This extends its half-life to approximately seven days, allowing once-weekly subcutaneous injection [1].

This is not a minor pharmacological achievement. Turning a two-minute peptide into a once-weekly medication while preserving receptor specificity and improving potency required sophisticated molecular engineering.

The Weight Loss Evidence

The STEP clinical trial program — four large randomized controlled trials involving over 4,500 participants — established semaglutide 2.4 mg weekly as the most effective pharmacological weight loss intervention available [2].

Key findings:

• STEP 1: Mean weight loss of 14.9% from baseline at 68 weeks versus 2.4% with placebo in adults with obesity without diabetes
• STEP 2: Mean weight loss of 9.6% in adults with obesity and type 2 diabetes
• STEP 3: Combined with intensive behavioral therapy, mean weight loss of 16.0%
• STEP 4: Patients who discontinued semaglutide after 20 weeks regained approximately two-thirds of their lost weight over the subsequent 48 weeks

The evidence is clear: semaglutide produces clinically meaningful weight loss in the majority of patients. But the STEP 4 result deserves equal emphasis — discontinuation leads to substantial weight regain. This is not a criticism of the drug; it reflects the biology of obesity. The hypothalamic setpoint mechanisms that drive weight regain are powerful, and semaglutide suppresses them only while it is active. If semaglutide is the right tool for you, plan for sustained use. Short courses followed by discontinuation rarely produce durable results.

Cardiovascular Benefits: The SELECT Trial

This is where semaglutide transcends weight loss. The SELECT trial enrolled over 17,600 adults with established cardiovascular disease and obesity (without diabetes) and randomized them to semaglutide 2.4 mg weekly versus placebo [3].

Results after a mean follow-up of 39.8 months:

• 20% reduction in major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke)
• Significant reductions in heart failure events
• Reduced all-cause mortality signal (not the primary endpoint but trending)

Let me put this in context. A 20% relative risk reduction in cardiovascular events is clinically significant. For comparison, statins — the cornerstone of cardiovascular prevention — achieved similar magnitudes in their landmark trials. The SELECT trial establishes semaglutide as a cardiovascular medication, not merely a weight loss drug.

The mechanism likely involves multiple pathways beyond weight loss: direct anti-inflammatory effects (CRP reductions of 37%), improvements in lipid profiles, reductions in visceral adiposity, and potentially direct effects on vascular endothelium. GLP-1 receptors are expressed at low levels in the heart and blood vessels, so direct effects on the cardiovascular system are possible alongside the indirect ones [4].

Neuroprotective Potential

This is where the evidence moves from strong to emerging — but the signals are compelling enough that they deserve attention.

GLP-1 receptors are widely expressed in the brain, particularly in the hippocampus, cortex, and substantia nigra. Preclinical studies demonstrate that GLP-1 receptor agonism:

• Reduces neuroinflammation (microglial activation)
• Enhances neuronal survival under metabolic stress
• Improves synaptic plasticity and long-term potentiation
• Reduces amyloid-beta and tau pathology in Alzheimer’s disease models
• Protects dopaminergic neurons in Parkinson’s disease models [5]

The human evidence is preliminary and, so far, disappointing. A Phase II trial of liraglutide (another GLP-1 agonist) in Alzheimer’s disease showed reduced cerebral glucose metabolism decline on PET imaging. Several epidemiological studies suggest lower rates of neurodegenerative disease in diabetic patients treated with GLP-1 agonists compared to other diabetes medications. Large clinical trials of semaglutide for Alzheimer’s disease (EVOKE and EVOKE Plus) reported in 2025 and did not slow Alzheimer’s progression (PMID 42785112). For a comprehensive breakdown of mechanisms, trial data, and patient selection for GLP-1 therapy specifically targeting cognitive longevity, see GLP-1 Agonists and Alzheimer’s Prevention: What the Evidence Shows in 2026.

I want to be precise about the evidence level: this is promising but preliminary for neurodegeneration. I treat the neuroprotective potential as a possible secondary benefit for people who have primary indications for semaglutide, not as a reason to use it solely for neuroprotection at this stage.

Anti-Inflammatory Effects

Beyond weight-loss-mediated inflammation reduction, GLP-1 receptor agonism appears to have direct anti-inflammatory properties:

• CRP reductions of 30-40% in the STEP and SELECT trials — larger than expected from weight loss alone
• Reduced IL-6 and TNF-alpha in both preclinical and clinical studies
• Improved endothelial function independent of metabolic parameters
• Effects on NASH/MASH: in a phase 2 trial, daily semaglutide 0.4 mg resolved NASH in 59% of patients against 17% on placebo, but fibrosis did not improve significantly more than with placebo [6]. In the phase 3 ESSENCE trial, weekly 2.4 mg resolved steatohepatitis in 62.9% against 34.3% and reduced fibrosis in 36.8% against 22.4% at 72 weeks [19]

For patients with chronic inflammatory conditions, including many people with post-COVID syndrome, Lyme sequelae and autoimmune conditions, the anti-inflammatory profile of semaglutide is clinically relevant.

The Muscle Loss Concern

Here is where I part company with the uncritical enthusiasm that surrounds semaglutide in some quarters.

Weight loss from semaglutide is not purely fat loss. Across trials of GLP-1-based drugs, lean mass has made up anything from about 15% to 40-60% of the weight lost, depending on the study [7]. Lean mass on a DXA scan also counts organs, bone and water, so it overstates muscle loss; MRI studies suggest the drop in muscle volume is roughly what the weight loss and age would predict, with better muscle quality [7]. In patients over 60, in patients with sarcopenia, in patients who are already physically frail, this is not a trivial concern.

The implications:

• Metabolic rate reduction: Muscle is metabolically active tissue. Losing it reduces basal metabolic rate, potentially making weight regain even more likely after discontinuation.
• Functional decline: In older adults, muscle loss translates directly to falls risk, mobility impairment, and loss of independence.
• Body composition paradox: A patient can lose 15% of body weight, appear thinner, and have a worse muscle-to-fat ratio than before treatment.

Semaglutide without resistance training is incomplete treatment. Structured resistance exercise two to three times weekly, adequate protein intake (1.2-1.6 g/kg/day), and in some cases targeted peptide support for muscle preservation (BPC-157, growth hormone secretagogues) should be standard components of any semaglutide protocol. These peptide add-ons have no trial evidence for muscle preservation on GLP-1 therapy, and several are on the FDA’s list of compounding substances that may present significant safety risks. For patients at higher sarcopenic risk, emerging data on combining bimagrumab with semaglutide — an investigational anti-myostatin antibody — suggest it may be possible to achieve fat loss and lean mass gain simultaneously, an outcome not achievable with GLP-1 therapy alone.

This is not optional. It is medically necessary to preserve the functional benefit of weight loss.

Gastrointestinal Side Effects

The GI side effect profile is the most common reason patients discontinue semaglutide:

• Nausea: Reported in 40-44% of patients in STEP trials, typically worst during dose escalation
• Vomiting: 24-25%
• Diarrhea: 30%
• Constipation: 24%

Most GI symptoms are transient and manageable with slow dose titration. The Wegovy label escalates in fixed steps, each held for four weeks: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, then 2.4 mg. If a step is not tolerated, the label allows the next increase to be delayed by four weeks, and many people hold each step for eight weeks instead of four (see the protocol table below).

However, more persistent GI complications also occur:

• Gastroparesis: Semaglutide’s effect on gastric motility can be excessive in susceptible individuals. Patients with pre-existing gastroparesis or diabetic neuropathy affecting the GI tract should be monitored carefully.
• Gallbladder disease: Rapid weight loss increases gallstone risk. The STEP trials showed higher rates of cholelithiasis in the semaglutide groups [2].
• Pancreatitis: Rare but reported. Any patient on semaglutide with severe abdominal pain needs prompt evaluation.

Who Should Consider Semaglutide

Based on the evidence and my clinical experience, semaglutide is most clearly indicated for:

1. Adults with BMI greater than 30 (or greater than 27 with weight-related comorbidities) who have not achieved adequate weight loss with lifestyle intervention alone
2. Adults with type 2 diabetes: particularly those with concurrent cardiovascular risk
3. Adults with established cardiovascular disease and obesity: the SELECT trial population
4. Patients with MASH and moderate to advanced liver fibrosis: the phase 3 ESSENCE trial showed resolution of steatohepatitis and less fibrosis at 72 weeks [19]

Patients seeking a non-prescription option with more modest metabolic effects may be better served by berberine — for a direct clinical comparison, see Berberine vs Semaglutide: What the Evidence Actually Shows. Patients who require greater weight-loss depth and have not reached target on semaglutide may progress to tirzepatide or, once approved, retatrutide — see Retatrutide vs Semaglutide vs Tirzepatide: The Triple Agonist Compared for a full clinical breakdown of the sequenced approach.

Who Should Not Use Semaglutide

• Personal or family history of medullary thyroid carcinoma or MEN2 syndrome — absolute contraindication based on rodent data showing thyroid C-cell tumors
• Active pancreatitis or history of severe pancreatitis
• Patients with active eating disorders: semaglutide’s appetite suppression can reinforce restrictive patterns
• Elderly patients with sarcopenia who cannot or will not engage in resistance training — the muscle loss risk outweighs the benefit
• Patients seeking a short-term solution: if you are unwilling to commit to sustained use and lifestyle changes, the rebound weight gain may leave you worse off

My Clinical Perspective

Semaglutide is best used selectively and always as part of a comprehensive protocol. Here is what I emphasise:

The metabolic improvements are real and rapid. Insulin sensitivity, inflammatory markers, and lipid profiles improve within weeks — often before significant weight loss occurs. This suggests direct pharmacological benefits independent of weight reduction.

Combination with peptide protocols. Semaglutide is often paired with BPC-157 for gut support (managing GI side effects and supporting mucosal integrity) and growth hormone secretagogues for muscle preservation. These combinations have not been tested in trials; see Peptide Stacking.

The psychological impact is significant. For patients who have struggled with obesity for decades, the reduction in food noise — the constant preoccupation with food — is often described as transformative. This is a real neurological effect mediated by central GLP-1 receptor agonism, and it should not be dismissed.

Individual dose optimization matters. Not every patient needs 2.4 mg weekly. Some achieve excellent results at 1.0 or 1.7 mg with fewer side effects. Rigid adherence to the maximum approved dose is not always optimal medicine.

The Compounding Question

I need to address compounded semaglutide directly. During the FDA shortage period, compounding pharmacies began producing semaglutide at significantly lower cost than the branded products (Ozempic, Wegovy). Now that the shortage is officially resolved, the legal and quality landscape is shifting.

My position: pharmaceutical-grade semaglutide from the manufacturer (Novo Nordisk) has undergone rigorous quality control, stability testing, and sterility verification. Compounded versions are not FDA-approved products and vary enormously in quality, and “research use only” semaglutide sold online is not a medicine at all. If you are using compounded semaglutide, sourcing and quality verification are paramount. This is an area where the supplement quality concerns I discuss frequently apply with equal force to compounded medications.

Practical Protocol

For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.

When I coach patients through starting semaglutide (mostly in the US), this is the protocol I walk them through with their prescriber:

1. Baseline assessment: Body composition (DEXA), metabolic panel, inflammatory markers, thyroid function, lipid panel, HbA1c, liver function
2. Dose titration: Start at 0.25 mg weekly and step up every four weeks through the label doses (0.5, 1, 1.7, then 2.4 mg), stopping at the dose that works (not necessarily the maximum)
3. Concurrent requirements: Resistance training prescription (minimum 2x/week, progressive overload), protein target (1.4-1.6 g/kg/day), adequate hydration
4. Monitoring: Monthly during titration (metabolic markers, GI symptoms, body composition). Quarterly once stable.
5. Body composition tracking: DEXA or bioimpedance at baseline, 3 months, 6 months, 12 months — to ensure lean mass preservation
6. Adjunctive support: As needed — BPC-157 for GI tolerance, vitamin and mineral optimization, longevity stack integration

Protocol table

Why label and practice doses differ. The label schedule uses fixed 4-week steps built around the STEP trials. The common real-world deviations go slower or lower: people hold a step longer, stop escalating once appetite is controlled, or settle on 1.7 mg, which the label allows. Microdosing at 0.125-0.25 mg has no trial behind it. In an electronic health record analysis of people kept on 0.25 mg for at least 6 months, mean weight change at 12 months was -2.2% (Murugadoss 2026); that is observational and does not tell us whether those patients were microdosing on purpose.

The two newest doses. The FDA approved semaglutide 7.2 mg weekly (Wegovy HD) in March 2026 (Novo Nordisk), and the European Commission approved it in February 2026, at first as three 2.4 mg injections given together (Novo Nordisk via BioSpace). In STEP UP, 7.2 mg produced a mean weight change of -18.7% at 72 weeks, against -15.6% with 2.4 mg and -3.9% with placebo (Wharton 2025). Oral Wegovy 25 mg was approved by the FDA in December 2025 (MedNous; label); in OASIS 4 it gave -13.6% at 64 weeks against -2.2% with placebo (Wharton 2025). The 50 mg oral dose from OASIS 1 (-15.1% at 68 weeks) was not brought to market (Knop 2023).

Compounded semaglutide. The FDA declared the semaglutide injection shortage resolved on 21 February 2025; the grace period ended for state-licensed compounding pharmacies in April 2025 and for outsourcing facilities on 22 May 2025 (FDA). Compounded vials are drawn up in millilitres or “units” on insulin syringes, which is where tenfold dosing errors come from (Lambson 2023).

What happens after stopping. In the STEP 1 extension, people regained about two-thirds of their lost weight within a year of stopping, and most cardiometabolic improvements drifted back towards baseline (Wilding 2022).

Technique, reconstitution and storage are in the peptide injection guide.

What people report: what works and what doesn’t

Sources: a qualitative analysis of 660 posts from a Wegovy subreddit (Plenn 2025), the INFORM survey of 550 users on food noise (Arnaut 2026), a machine-learning analysis of Reddit posts on alcohol plus a small remote study (Quddos 2023), an aggregated community data set (Peptide Protocol Wiki, 500 reports), a meta-analysis on hair loss (Viquez Burboa 2026), a report on microdosing and compounding practice (Trainer 2026), and the trial data above. Patterns, not proof.

Reported to work

• Appetite suppression within the first one to two weeks, long before the maintenance dose is reached.
• Quieter “food noise”. In INFORM, the median Food Noise Questionnaire score fell from 13 to 6 out of 20, and agreement with statements describing food noise fell from 47-63% before treatment to 15-20% after. This was recalled, not measured prospectively.
• Weight loss of roughly 8-18% over 6 to 12 months in community aggregates, broadly in line with the STEP trials.
• Less interest in alcohol. Of 1,580 alcohol-related Reddit posts, 71% described reduced craving or desire to drink, and a small remote study found lower self-reported intake in people taking semaglutide or tirzepatide.

Mixed or unclear

• Microdosing for inflammation, longevity or “metabolic health”. Widely discussed, never tested in a trial. Patients usually turn to it for GI tolerability, cost or modest cosmetic weight goals, and dosing errors still happen at these doses (Trainer 2026). The only real-world weight data at 0.25 mg show about 2% loss at a year.
• Low maintenance doses of 0.5-1 mg. Used to limit GI side effects; whether they hold weight over years has not been studied for weight management.
• Compounded product. Cheaper, but concentration and dosing units vary between pharmacies, and the dosing errors cluster here.
• Slow or uneven progress. Reddit users describe discouragement when others lose weight on doses that do little for them. In STEP 1, 13.6% of participants on 2.4 mg lost less than 5% at 68 weeks.

Reported not to work, or disappointing

• Keeping the weight off after stopping. The most common complaint, and the trials predict it: about two-thirds regained within a year.
• Hair shedding. Telogen effluvium was more frequent at 12 months in GLP-1 users (adjusted odds ratio 1.76), and semaglutide carried the strongest pharmacovigilance signal for hair loss among the drugs analysed.
• Muscle and strength loss without resistance training, as discussed in the muscle section above.
• Side effects people stop for: nausea, diarrhoea, constipation (in some posts severe enough for an emergency visit), headache and fatigue. In STEP 1, 4.5% stopped because of GI events.
• Cost and access. About one in ten coded Reddit references concerned cost, insurance loss or supply.

What a properly designed trial would need to show: for microdosing and low-dose maintenance, a randomised, placebo-controlled trial of at least 12 months comparing 0.125-0.25 mg and 0.5-1 mg weekly with the labelled dose, with hsCRP and IL-6, insulin sensitivity, DXA body composition and weight trajectory after stopping as prespecified endpoints.

Safety and Considerations

• Thyroid monitoring: While the medullary thyroid carcinoma signal was seen only in rodents at much higher doses, thyroid function monitoring is prudent
• Renal function: Dehydration from GI side effects can impair renal function. Adequate hydration is essential.
• Drug interactions: Delayed gastric emptying can affect absorption of oral medications. Timing of oral contraceptives, levothyroxine, and other time-sensitive medications should be reviewed.
• Mental health: While most patients report improved well-being, some report depressive symptoms. Any mood changes should be reported and evaluated.

The Bottom Line

Semaglutide is a genuinely important medication with strong evidence for weight management, cardiovascular risk reduction, and promising signals for neuroprotection and anti-inflammatory effects. It is not a cosmetic convenience or a shortcut. It is a pharmacological tool that, when used thoughtfully — with resistance training, adequate protein, proper monitoring, and realistic expectations about sustained use — produces meaningful clinical benefit. The question is not whether semaglutide works. The question is whether it is the right tool for your specific situation, and whether you are prepared to use it correctly. That conversation belongs in a physician’s office, not on a social media feed.